Pharmacogenomics research and clinical implementation in Brazil

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Ethical considerations in clinical pharmacogenomics research.

In recent years there have been unprecedented advances in our understanding of the involvement of genetic polymorphisms in the response to drug therapies. Polymorphisms have been identified that lead to variable patient responses to several medications including cardiovascular, psychiatric, anti-infective and analgesic therapies. The potential for the development of customized, genotype-based t...

Clinical research in Brazil

Clinical research is extremely important to advance medical care. It is impossible to predict how a drug will perform in humans given their complexities, based only on in vitro and animal studies. On the other hand protection of research subjects is not only a scientific question but one of human rights, vis-a-vis the recent past when abuses were committed even in the so-called civilized societ...

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Severe cutaneous adverse reactions (SCARs), previously thought to be idiosyncratic or unpredictable, are a deadly form of adverse drug reactions with skin manifestations. Current pharmacogenomic studies of SCARs have made important strides, as the prevention of SCARs, to some extent, appears attainable with the identification of genetic variants for genes encoding drug-metabolizing enzymes and ...

Pharmacogenomics in Clinical Practice

The Promise of Pharmacogenomics As genomic medicine advances, there is hope that genetic biomarkers will encourage movement away from empirical and population-based treatment approaches to those that are stratified according to better patient outcomes, thus ending a “trial-and-error” approach to therapy.4,6–8 It is estimated that only 50% of patients respond positively to their medications.5,9 ...